To hear about similar clinical trials, please enter your email below
Trial Title:
Dexamethasone Versus Mg Added to Bupivacaine Used in ESPB for Perioperative Pain Control in Patients Undergoing Unilateral Nephrectomy
NCT ID:
NCT06501079
Condition:
Renal Neoplasm
Conditions: Official terms:
Kidney Neoplasms
Bupivacaine
Conditions: Keywords:
Dexamethasone
Magnesium Sulphate
Bupivacaine
Erector Spinae Plane Block
perioperative
pain control
unilateral nephrectomy
Study type:
Interventional
Study phase:
N/A
Overall status:
Recruiting
Study design:
Allocation:
Randomized
Intervention model:
Parallel Assignment
Intervention model description:
The aim of the current study is to compare the effect of adding dexamethasone versus
magnesium sulphate to bupivacaine in ultrasound-guided erector spinae plane block on the
severity of postoperative pain.
Primary Objectives to compare the effect of ESPB without additives to the effect of
adding dexamethasone and to the effect of adding magnesium sulphate in the form of
post-operative visual analogue scale (VAS) after 30 hours at rest.
Primary purpose:
Supportive Care
Masking:
Double (Participant, Investigator)
Intervention:
Intervention type:
Procedure
Intervention name:
ultrasound guided Erector Spinae Plane Block using 27ml bupivacaine 0.25%
Description:
ESP block will be performed U/S at the level of T 10 paraspinal level. The ultrasound
transducer should be placed in the midline of the back at the desired level. The probe
should then slowly be moved laterally until the transverse process is visible. The
transverse process requires differentiation from the rib at that level.
Erector spinae muscle should be identified superficial to the transverse process. The
needle inserted superior to the ultrasound probe in the cephalad to caudal direction.
Once the needle tip is below the erector spinae muscle.
This separation from the transverse process confirms the proper needlemposition.
The local anesthetic should then be injected in 5 ml increments. The block will be
performed preoperatively.
Arm group label:
Normal saline
Arm group label:
dexamethasone
Arm group label:
magnesium sulphate 10%
Summary:
Aim of the study:
The current study aims to compare the effect of adding dexamethasone versus magnesium
sulfate to bupivacaine in ultrasound-guided erector spinae plane block on the severity of
postoperative pain.
Primary Objectives:
- To compare the effect of ESPB without additives to the effect of adding
dexamethasone and to the impact of adding magnesium sulfate in the form of
post-operative morphine consumption
Detailed description:
Aim of the study:
The current study aims to compare the effect of adding dexamethasone versus magnesium
sulfate to bupivacaine in ultrasound-guided erector spinae plane block on the severity of
postoperative pain and postoperative morphine consumption.
Methodology:
I. Study design:
This is a randomized Controlled Study. It will involve three groups: Control Group (C)
receiving erector spinae block with 27ml bupivacaine 0.25% + 3 ml NS, Group (M) receiving
27 ml bupivacaine 0.25% + 3 ml magnesium sulphate 10%, Group (D) receiving 27 ml
bupivacaine 0.25% + 8 mg dexamethasone (2 ml) + 1 ml NS.
II. Study setting and location:
National Cancer Institute, Cairo University after approval by the institutional review
board.
III. Study population:
Adult patients undergoing unilateral nephrectomy under general anesthesia.
Patients will be randomly assigned to the groups using online random number generator.
Erector Spinae Plane Block technique:
Informed consent, including the risks and benefits of the procedure, should be obtained
before carrying out an ESP block. A peri-procedural "timeout" should be performed to
confirm the type, side, and location of the procedure and ensure that there are no
contraindications.
Standard patient monitoring should be in place, including continuous ECG monitoring,
pulse oximetry, and blood pressure measurement in at least 5-minute intervals. Patients
should be prepped and draped in sterile conditions. Sterile gloves and surgical cap and a
mask are necessary, and the ultrasound probe is placed into the sterile ultrasound probe
cover for imaging. The ESP block will be performed at the level of T 10 paraspinal level.
The ultrasound transducer should be placed in a cephalocaudal orientation over the
midline of the back at the desired level. The probe should then slowly be moved laterally
until the transverse process is visible. The transverse process requires differentiation
from the rib at that level. The transverse process will be more superficial and wider,
while the rib will be deeper and thinner. Erector spinae muscle should be identified
superficial to the transverse process. The needle should be inserted superior to the
ultrasound probe using an in-plane approach in the cephalad to caudal direction. Once the
needle tip is below the erector spinae muscle, a small bolus of local anesthetic should
be given through the needle. The erector spinae muscle should be visualized, separating
from the transverse process. This separation from the transverse process confirms the
proper needle position.
The local anesthetic should then be injected in 5 ml increments, with aspiration after
every 5 ml to prevent intravascular injection. Block will be performed preoperatively in
the preoperative holding area.
Heart rate and blood pressure to be recorded preoperative, intraoperative and
postoperatively
Assessment of pain:
Pain assessment will be done through Visual Analogue Scale. Patients should be informed
preoperatively about it and how to use this scale. Starting from recovery time, pain
assessment is done by asking the patient to mark the intensity of pain perceived and
express it on a 10 cm horizontal scale ranging from no pain at one end to the worst
possible pain at the other end.
Assessment of pain is to be done in the recovery unit and at 0,2,4,8,12,18, 24 and 30
hours postoperatively.
Total amount of opioid needed in first 24 hours to be recorded.
Rescue Analgesia:
Intraoperative rescue analgesia will be done by giving fentanyl at dose of 1 mic/Kg.
Postoperatively, NSAIDs such as Ketorolac 30 mg I.V infusion if VAS is between 3 to 6,
and Morphine 3 mg I.V if VAS equals or is more significant than 6.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
- Adult (18 - 65)
- Patients undergoing unilateral nephrectomy
- ASA II / III
Exclusion Criteria:
- Patient refusal
- Age less than 18 years
- Allergy to any of the studied medications
- Mid line incision
- Bilateral nephrectomy
- Distorted anatomy of the back (e.g. kyphoscoliosis)
- Known neurologic disorders, psychiatric disorder or chronic pain
- Local infection
- Hemodynamic instability
Gender:
All
Minimum age:
18 Years
Maximum age:
65 Years
Healthy volunteers:
No
Locations:
Facility:
Name:
National Cancer institute - Cairo University
Address:
City:
Cairo
Country:
Egypt
Status:
Recruiting
Contact:
Last name:
attef
Phone:
0225328286
Email:
irb@nci.cu.edu.eg
Investigator:
Last name:
Ahmed M soliman, lecturer
Email:
Principal Investigator
Investigator:
Last name:
kamal H Youssef, Dr
Email:
Sub-Investigator
Investigator:
Last name:
Noha M Abdelmoneim, lecturer
Email:
Sub-Investigator
Investigator:
Last name:
essam Mahran, profess
Email:
Sub-Investigator
Investigator:
Last name:
gehan kam, profess
Email:
Sub-Investigator
Start date:
May 1, 2024
Completion date:
December 1, 2024
Lead sponsor:
Agency:
National Cancer Institute, Egypt
Agency class:
Other
Source:
National Cancer Institute, Egypt
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT06501079